Month: February 2024

MediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYL

by

(RTTNews) – MediWound Ltd. (MDWD) Monday reported positive results from head-to-head comparison analyses of the company’s lead asset EscharEx for the treatment of chronic wounds to SANTYL ointment. SANTYL was approved by the FDA for debriding chronic dermal ulcers. Results from the secondary analyses of the Phase II ChronEx study showed that EscharEx was superior … Read more

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

by

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. … Read more